Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019027117) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING RECEPTOR TYROSINE KINASE INHIBITOR AS ACTIVE INGREDIENT
Latest bibliographic data on file with the International Bureau    Submit observation
Pub. No.: WO/2019/027117 International Application No.: PCT/KR2018/002500
Publication Date: 07.02.2019 International Filing Date: 28.02.2018
IPC:
A61K 31/4439 (2006.01) ,A61K 31/443 (2006.01) ,A61K 31/421 (2006.01) ,A61K 45/06 (2006.01) ,A23L 33/10 (2016.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
4439
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
443
containing a five-membered ring with oxygen as a ring hetero atom
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42
Oxazoles
421
1,3-Oxazoles, e.g. pemoline, trimethadione
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
[IPC code unknown for A23L 33/10]
Applicants:
한국원자력의학원 KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES [KR/KR]; 서울시 노원구 노원로 75 (공릉동) (Gongneung-dong) 75, Nowon-ro Nowon-gu Seoul 01812, KR
Inventors:
안지연 ANN, Ji Yeon; KR
송지영 SONG, Jie Young; KR
최현경 CHOI, Hyun-Kyoung; KR
유화니 RYU, Hwa Ni; KR
황상구 HWANG, Sang Gu; KR
남기엽 NAM, Ky-Youb; KR
정인성 JUNG, In-Sung; KR
Agent:
특허법인 태백 TAEBAEK INTELLECTUAL PROPERTY LAW FIRM; 서울시 금천구 가산디지털1로151 이노플렉스1차 601호 #601 Innoplex 1 cha, 151Gasandigital 1-ro Geumcheon-gu Seoul 08506, KR
Priority Data:
10-2017-009852403.08.2017KR
Title (EN) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING RECEPTOR TYROSINE KINASE INHIBITOR AS ACTIVE INGREDIENT
(FR) COMPOSITION PHARMACEUTIQUE PERMETTANT DE PRÉVENIR OU DE TRAITER LE CANCER CONTENANT UN INHIBITEUR DU RÉCEPTEUR TYROSINE KINASE EN TANT QUE PRINCIPE ACTIF
(KO) 수용체 티로신 키나아제 저해제를 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
Abstract:
(EN) The present invention relates to a receptor tyrosine kinase activity inhibiting compound represented by Chemical Formula 1 and Chemical Formula 2, wherein the compound represented by Chemical Formula 1 and Chemical Formula 2 has been confirmed to inhibit the growth of cancer cells through inhibiting kinase activity and has been confirmed to enhance cancer cell apoptosis when used in combination with existing anticancer drugs or radiation therapy. Accordingly, the compound represented by Chemical Formula 1 and Chemical Formula 2 can be provided as a pharmaceutical composition for preventing or treating cancer, or as a composition for increasing the anti-cancer treatment effect of anti-cancer treatments and radiation therapy.
(FR) La présente invention concerne un composé inhibiteur de l'activité du récepteur tyrosine kinase représenté par la formule chimique 1 et la formule chimique 2, le composé représenté par la formule chimique 1 et la formule chimique 2 ayant montré qu'il inhibait la croissance de cellules cancéreuses par l'inhibition de l'activité de la kinase et qu'il améliorait l'apoptose des cellules cancéreuses lorsqu'il était utilisé en combinaison avec des médicaments anticancéreux existants ou une radiothérapie existante. Par conséquent, le composé représenté par la formule chimique 1 et la formule chimique 2 peut être fourni en tant que composition pharmaceutique pour prévenir ou traiter le cancer, ou en tant que composition pour augmenter l'effet de traitement anticancéreux dans le cas de traitements anticancéreux et de radiothérapie.
(KO) 본 발명은 화학식 1 및 화학식 2로 표시되는 수용체 티로신 키나아제 활성 억제 화합물에 관한 것으로, 상기 화학식 1 또는 화학식 2와 같이 표시되는 화합물은 키나아제 활성 억제를 통하여 암세포의 성장을 억제하는 것을 확인하였으며, 종래의 항암제 또는 방사선 치료와 병용처리할 경우, 암세포의 아팝토시스 사멸효과가 향상되는 것으로 확인됨에 따라, 상기 화학식 1 또는 화학식 2와 같이 표시되는 화합물은 암 예방 또는 치료용 약학조성물 또는 항암치료 및 방사선 치료의 항암 치료 효과 증진용 조성물로 제공될 수 있다.
 front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)